Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

NCT02415608 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Aggressive Systemic Mastocytosis
Mast Cell Leukemia
Systemic Mastocytosis

Interventions

DRUG: Ibrutinib

Sponsor

Jason Robert Gotlib

Collaborators

[object Object]